Results 221 to 230 of about 69,822 (254)

Advances in retinal pigment epithelium transplantation for age-related macular degeneration: bridging biology to therapeutic frontiers. [PDF]

Stem Cell Res Ther
Bhargava M, Mehta KN, Parikh BH, Liu Z, Su X.   +4 more
europepmc   +1 more source

Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability [PDF]

AAPS PharmSciTech, 2017
To ensure consistency of clinical outcomes, orally inhaled therapies must exhibit consistent delivered dose and aerosol properties at the time of manufacturing, throughout storage, and during various patient-use conditions. Achieving consistency across these scenarios has presented a significant challenge, especially for combination products that ...
David Lechuga-Ballesteros
exaly   +3 more sources

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD

Pulmonary Pharmacology and Therapeutics, 2020
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI), formulated using co-suspension delivery technology, is a triple fixed-dose combination in late-stage clinical development for chronic obstructive pulmonary disease (COPD).We conducted two studies to characterize the pharmacokinetic (PK) profile of BGF MDI in patients with ...
Edward M Kerwin, Kiernan Deangelis, Patrick Darken   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthma

Allergy and Asthma Proceedings, 2018
This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma.To characterize the effects of BD delivered by MDI on lung function and safety.Randomized, double-blind, 4-week cross-over, placebo-controlled, phase IIb study of adults ...
S David Miller, Shahid Siddiqui, Paul Dorinsky   +2 more
exaly   +3 more sources

Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases [PDF]

Respiratory Medicine, 2018
Technologies for long-term delivery of aerosol medications in asthma and chronic obstructive pulmonary disease have improved over the past 2 decades with advancements in our understanding of the physical chemistry of aerosol formulations, device engineering, aerosol physics, and pulmonary biology.
Gary T Ferguson, Anthony J Hickey
exaly   +3 more sources

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease [PDF]

Respiratory Medicine, 2017
The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination metered dose inhaler (GFF MDI) were investigated in a 28-week safety extension study (PINNACLE-3, NCT01970878) of two randomized controlled Phase III trials (PINNACLE-1 and -2; NCT01854645 and ...
Nicola A Hanania, Donald P Tashkin, Edward M Kerwin   +2 more
exaly   +3 more sources

Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects

Pulmonary Pharmacology and Therapeutics, 2018
Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance ...
Colin Reisner, Andrea Maes, Shahid Siddiqui   +2 more
exaly   +3 more sources

Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease

Respiratory Investigation, 2021
PINNACLE-4 evaluated the efficacy and safety of the long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in patients from Asia, Europe, and the USA with moderate-to-very severe chronic obstructive pulmonary disease (COPD).
Yasuhiro, Gon, Koichi, Nishi, Kazuhiro, Sato, Andrea, Maes, Shahid, Siddiqui, Nobuya, Hayashi, Hajime, Hirata, Ubaldo J, Martin, Colin, Reisner   +8 more
openaire   +2 more sources